Day 1 | Day 2 | Download Brochure
Wednesday, June 6
12:30 pm Registration
1:20 Chairperson’s Opening Remarks
» 1:25 KEYNOTE PRESENTATION
From Mechanisms to Medicines: What ACTTION Can be Taken to Accelerate Analgesic Drug Development?
Robert H. Dworkin, Ph.D., Professor of Anesthesiology, Neurology, Oncology, and Psychiatry; Professor, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry; Director, Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the FDA
|
2:10 A Novel Genetic Based Approach for Demonstrating Target Engagement of Nav1.7 Inhibitors
Y. Paul Goldberg, M.B., Ch.B., Ph.D., FRCPC, Vice-President, Clinical Development, Xenon Pharmaceuticals, Inc.
2:40 Pharmacology and First Clinical Experience of the Dual Enkephalinase Inhibitor PL37
Bernard P. Roques, Ph.D., Vice President & Scientific Director, Pharmaleads
Michel Wurm, M.D., Director, Drug and Business Development, Pharmaleads
3:10 Sponsored Presentations (Opportunities Available)
3:40 Refreshment Break in the Exhibit Hall with Poster Viewing
4:10 Talk Title to be Announced
Anthony W. Bannon, Ph.D., Associate Director II, Neuroscience Drug Discovery, Global Pharmaceutical Research & Development, Abbott
4:40 Interactive Discussion Groups
Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.
5:40 End of Day
Day 1 | Day 2 | Download Brochure